Sick leave and disability pension following delivery in women with systemic lupus erythematosus

Objective: To investigate sickness benefits following delivery in mothers with systemic lupus erythematosus (SLE) and mothers without SLE. Method: SLE and non-SLE mothers, matched by age and month of delivery, with a singleton liveborn (2004–2008), were identified from the Swedish Lupus Linkage cohort. Work loss (sum of sick leave and disability pension) was studied from 1 year prenatally to 3 years postpartum. Adjusted logistic regression models of covariates associated with > 30 days of work loss in the first and second years postpartum were estimated in SLE mothers. Results: Among 130 SLE mothers and 440 non-SLE mothers, SLE mothers were more likely to have work loss from the prenatal year (42% vs 16%) to 3 years postpartum (49% vs 15%). In SLE mothers, work loss was on average 61 ± 112 days (mean ± sd) in the prenatal year and 38 ± 83 days in the first year postpartum, which increased to 71 ± 114 days in the third year postpartum. Having > 30 days of sick leave in the year of delivery [odds ratio (OR) 4.4, 95% confidence interval (CI) 1.5–12.9] and ≤ 12 years of education (OR 2.6, 95% CI 1.1–6.0) were associated with work loss in the first year postpartum. No covariates were associated with work loss in the second year postpartum. Conclusion: SLE mothers more often had work loss in the prenatal year to 3 years postpartum compared to non-SLE mothers. Lower education and sick leave in the year of delivery were associated with a higher odds of work loss in the first year postpartum in SLE

Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study

Systemic Lupus Erythematosus (SLE) is an autoimmune, inflammatory disease that mainly affects women. The prognosis of SLE has improved dramatically, but mortality rates are still higher than in the general population. With the improved general prognosis, cardiovascular disease (CVD) has emerged as a major cause of morbidity and mortality among SLE patients. Previous studies have demonstrated that the development of atherosclerosis is accelerated in SLE, and have identified a set of traditional and nontraditional risk factors that characterize SLE patients with CVD. Nevertheless, many unsolved issues with respect to SLE related CVD remain. The general aim of this thesis was to investigate risk factors for manifest CVD and for cardiovascular mortality (CVM) in SLE, with special focus on traditional risk factors, lupus phenotype, inflammatory and endothelial biomarkers, autoantibodies and genetic predisposition. In the first paper, we prospectively studied traditional and non-traditional risk factors for the development of the first cardiovascular event (CVE) in 182 SLE patients with a follow-up time of 8 years. 24(13%) patients had a first event. We demonstrated that of the traditional risk factors, only age and smoking predicted the first CVE. Additionally, antiphospholipid antibodies (aPL), endothelial biomarkers, represented by soluble vascular cell adhesion molecule 1(sVCAM-1), and absence of thrombocytopenia were independent predictors of CVE. Thus, activation of the endothelium and the coagulation system are important features in SLE-related CVD and the importance to advocate smoking cessation among SLE patients is underscored In the second paper, we prospectively investigated causes of mortality and risk factors for overall mortality and CVM in a cohort of 208 SLE patients, with a follow-up time of 12 years. We also evaluated Systematic coronary risk evaluation (SCORE, tool for evaluating the 10 year risk for cardiovascular death in the age span 40-65 years, based on traditional risk factors) in this population. Cystatin C, a sensitive measure of renal function, in addition to traditional and non-traditional risk factors, were evaluated as risk factors. 42 patients died, 48 % of which were due to CVM. Age, previous arterial events and high cystatin C levels were the strongest predictors for overall mortality and for CVM. After adjusting for these three variables, smoking, sVCAM-1 and high sensitiviy C-reactive protein (hsCRP) predicted CVM. SCORE estimated 4 but we observed 9 cases of CVM, a non-significant difference. We conclude that except for smoking, traditional risk factors are less important than cystatin C, endothelial and inflammatory biomarkers as predictors of CVM in SLE patients. In the third paper, we investigated whether a risk allele for SLE in the signal transducer and activator of transcription factor 4 gene (STAT4) was associated with vascular events or presence of antiphospholipid antibodies (aPL). A total of 578 unrelated SLE patients (424 from mid-Sweden and 154 from southern-Sweden) were included in a cross-sectional design. Occurrence of previous cardiovascular events and aPL were tabulated. Matched controls (N=651) were genotyped as a comparison. The results demonstrate that the STAT4 risk allele was associated with ischemic cerebrovascular disease (ICVD), with a dose-dependent relationship between ICVD and number of risk alleles. The risk allele was furthermore associated with the presence of two or more aPLs, also in a dose-dependent manner. The association remained after adjustment for known traditional risk factors. We conclude that patients with the STAT4 risk allele have an increased risk of ICVD. Our results imply that genetic predisposition is an important risk factor for ICVD in SLE patients, and that aPL may be one underlying mechanism. In the fourth paper, we evaluated the potential association between smoking and aPL. 367 SLE patients were investigated in a cross-sectional study. Occurrence of aPL (anticardiolipin (aCL) IgG and IgM, anti-β2 glycoprotein-1 IgG (aβ2GP1 IgG), lupus anticoagulant (LAC)) and smoking habits (never, ever, former, current) were tabulated. Never smoking was used as reference in all calculations. In multivariable models, adjusted for age, sex and age at disease onset, aCL and aβ2GP1 of the IgG isotype and LAC were associated with ever smoking, this association seemed to be driven mainly by the former smoking group. Our results demonstrate that smoking is associated with pro-thrombotic aPL in SLE patients, though we can not from this study draw firm conclusions about the temporal relationship between exposure to smoking and occurrence of aPL. Further studies are warranted to investigate the mechanisms behind these observations. In prospective studies we have demonstrated that in particular smoking, systemic inflammation, endothelial activation and aPL are major risk factors for SLE related CVD and CVM. Furthermore, genetic predisposition, in our studies represented by a STAT4 SLE risk allele, contributes to the high risk of ICVD and to the occurrence of aPL, a possible underlying pathogenic mechanism. Finally we demonstrate that smoking, known to have unfavorable effects on the immune system and to significantly increase cardiovascular risk in SLE patients, is also associated with pro-thrombotic aPL in patients with SLE. Thus in SLE smoking stands out as the most important of the traditional risk factors with potential influence also on lupus related risk factors such as aPL

A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts

© 2018, The Author(s). Systemic lupus erythematosus (SLE) is an autoimmune disorder with heterogeneous clinical presentation and complex etiology involving the interplay between genetic, epigenetic, environmental and hormonal factors. Many common SNPs identified by genome wide-association studies (GWAS) explain only a small part of the disease heritability suggesting the contribution from rare genetic variants, undetectable in GWAS, and complex epistatic interactions. Using targeted re-sequencing of coding and conserved regulatory regions within and around 215 candidate genes selected on the basis of their known role in autoimmunity and genes associated with canine immune-mediated diseases, we identified a rare regulatory variant rs200395694:G > T located in intron 4 of the MEF2D gene encoding the myocyte-specific enhancer factor 2D transcription factor and associated with SLE in Swedish cohorts (504 SLE patients and 839 healthy controls, p = 0.014, CI = 1.1–10). Fisher’s exact test revealed an association between the genetic variant and a triad of disease manifestations including Raynaud, anti-U1-ribonucleoprotein (anti-RNP), and anti-Smith (anti-Sm) antibodies (p = 0.00037) among the patients. The DNA-binding activity of the allele was further studied by EMSA, reporter assays, and minigenes. The region has properties of an active cell-specific enhancer, differentially affected by the alleles of rs200395694:G > T. In addition, the risk allele exerts an inhibitory effect on the splicing of the alternative tissue-specific isoform, and thus may modify the target gene set regulated by this isoform. These findings emphasize the potential of dissecting traits of complex diseases and correlating them with rare risk alleles with strong biological effects

No evidence of association between genetic variants of the PDCD1 ligands and SLE

To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldPDCD1, an immunoreceptor involved in peripheral tolerance has previously been shown to be genetically associated with systemic lupus erythematosus (SLE). PDCD1 has two ligands whose genes are located in close proximity on chromosome 9p24. Our attention was drawn to these ligands after finding suggestive linkage to a marker (gata62f03, Z=2.27) located close to their genes in a genome scan of Icelandic families multiplex for SLE. Here, we analyse Swedish trios (N=149) for 23 single nucleotide polymorphisms (SNPs) within the genes of the PDCD1 ligands. Initially, indication of association to eight SNPs was observed, and these SNPs were therefore also analysed in Mexican trios (N=90), as well as independent sets of patients and controls from Sweden (152 patients, 448 controls) and Argentina (288 patients, 288 controls). We do not find support for genetic association to SLE. This is the first genetic study of SLE and the PDCD1 ligands and the lack of association in several cohorts implies that these genes are not major risk factors for SLE.Genes and Immunity (2007) 8, 69-74. doi:10.1038/sj.gene.6364360; published online 30 November 2006

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion

A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5

Systemic lupus erythematosus (SLE) is the prototype autoimmune disease where genes regulated by type I interferon (IFN) are over-expressed and contribute to the disease pathogenesis. Because signal transducer and activator of transcription 4 (STAT4) plays a key role in the type I IFN receptor signaling, we performed a candidate gene study of a comprehensive set of single nucleotide polymorphism (SNPs) in STAT4 in Swedish patients with SLE. We found that 10 out of 53 analyzed SNPs in STAT4 were associated with SLE, with the strongest signal of association (P = 7.1 × 10−8) for two perfectly linked SNPs rs10181656 and rs7582694. The risk alleles of these 10 SNPs form a common risk haplotype for SLE (P = 1.7 × 10−5). According to conditional logistic regression analysis the SNP rs10181656 or rs7582694 accounts for all of the observed association signal. By quantitative analysis of the allelic expression of STAT4 we found that the risk allele of STAT4 was over-expressed in primary human cells of mesenchymal origin, but not in B-cells, and that the risk allele of STAT4 was over-expressed (P = 8.4 × 10−5) in cells carrying the risk haplotype for SLE compared with cells with a non-risk haplotype. The risk allele of the SNP rs7582694 in STAT4 correlated to production of anti-dsDNA (double-stranded DNA) antibodies and displayed a multiplicatively increased, 1.82-fold risk of SLE with two independent risk alleles of the IRF5 (interferon regulatory factor 5) gene

Multilocus Genotyping of Human Giardia Isolates Suggests Limited Zoonotic Transmission and Association between Assemblage B and Flatulence in Children

Giardia intestinalis is a protozoan parasite found world-wide and it is a major cause of diarrhea in humans and other mammals. The genetic variability within G. intestinalis is high with eight distinct genotypes or assemblages (A-H). Here we performed sequence-based multilocus genotyping of around 200 human Giardia isolates. We found evidence of limited zoonotic transmission of certain A subtypes and an association between flatulence and assemblage B infection in children. This shows that it is important to investigate different assemblages and sub-assemblages of G. intestinalis in human infections in order to understand the clinical significance, zoonotic potential, sequence divergence, and transmission pathways of this parasite

EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.

OBJECTIVES: Develop recommendations for women's health issues and family planning in systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). METHODS: Systematic review of evidence followed by modified Delphi method to compile questions, elicit expert opinions and reach consensus. RESULTS: Family planning should be discussed as early as possible after diagnosis. Most women can have successful pregnancies and measures can be taken to reduce the risks of adverse maternal or fetal outcomes. Risk stratification includes disease activity, autoantibody profile, previous vascular and pregnancy morbidity, hypertension and the use of drugs (emphasis on benefits from hydroxychloroquine and antiplatelets/anticoagulants). Hormonal contraception and menopause replacement therapy can be used in patients with stable/inactive disease and low risk of thrombosis. Fertility preservation with gonadotropin-releasing hormone analogues should be considered prior to the use of alkylating agents. Assisted reproduction techniques can be safely used in patients with stable/inactive disease; patients with positive antiphospholipid antibodies/APS should receive anticoagulation and/or low-dose aspirin. Assessment of disease activity, renal function and serological markers is important for diagnosing disease flares and monitoring for obstetrical adverse outcomes. Fetal monitoring includes Doppler ultrasonography and fetal biometry, particularly in the third trimester, to screen for placental insufficiency and small for gestational age fetuses. Screening for gynaecological malignancies is similar to the general population, with increased vigilance for cervical premalignant lesions if exposed to immunosuppressive drugs. Human papillomavirus immunisation can be used in women with stable/inactive disease. CONCLUSIONS: Recommendations for women's health issues in SLE and/or APS were developed using an evidence-based approach followed by expert consensus